Skip to content
DataLookout
Menu

NCT06685354

Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Objective response rate (ORR)
Timeframe: Generally, the ORR is assessed for each participant every two treatment cycles(each cycle is 3 weeks).

Secondary (4)

Disease control rate (DCR)
Duration of response (DoR)
Progression-Free Survival (PFS)
Overall Survival (OS)

Arms and interventions

experimental groupExperimental

The participants will receive hepatic arterial infusion of recombinant human adenovirus type 5 injection in combination with first-line targeted and immunotherapy as recommended by the 2024 primary liver cancer treatment guidelines.

Drugs: hepatic arterial infusion of recombinant human type 5 adenovirus

Sites

1 site in 1 country

  • The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalZhengzhou, Henan, China